Prevalence of telogen effluvium hair loss in COVID-19 patients and its relationship with disease severityObservational Study Published on 2022-05-012022-10-04 Journal: Journal of Medicine and Life [Category] 임상, [키워드] addition age common Comorbidities concerning consequence COVID-19 COVID-19 pandemic COVID-19 patient COVID-19 patients cross-sectional detect discharge disease severity female Fever global pandemic hair loss. male manifestation medication Patient patients PCR test positive Prevalence ranged reported respiratory symptoms Stress Telogen telogen effluvium was performed [DOI] 10.25122/jml-2021-0380 PMC 바로가기 [Article Type] Observational Study
App-based COVID-19 syndromic surveillance and prediction of hospital admissions in COVID Symptom Study Sweden Research Published on 2022-04-212022-10-05 Journal: Nature Communications [Category] 임상, 치료기술, [키워드] 95% CI AUC contribute contributed COVID COVID-19 COVID-19 test dataset English enrolled error rate FIVE highlighting hospital Hospital admission Hospital admissions include Local median observé pandemic PCR test predict Prevalence Probability Region second wave study participant Surveillance Symptom symptomatic turn [DOI] 10.1038/s41467-022-29608-7 [Article Type] Research
Emulation of a Target Trial From Observational Data to Compare Effectiveness of Casirivimab/Imdevimab and Bamlanivimab/Etesevimab for Early Treatment of Non-Hospitalized Patients With COVID-19COVID-19로 입원하지 않은 환자의 조기 치료를 위한 Casirivimab/Imdevimab 및 Bamlanivimab/Etesevimab의 효과를 비교하기 위한 관찰 데이터의 표적 시험 에뮬레이션Clinical Trial Published on 2022-04-202022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 변종, 임상, 진단, [키워드] adjusted allocation Alpha Analysis ANCOVA bamlanivimab bamlanivimab/etesevimab baseline carried Casirivimab casirivimab/imdevimab Combination Comparative analysis COVID-19 Cox model Ct value cycle threshold death Delta determine early treatment early treatment for COVID-19 Effectiveness enrolment etesevimab evaluated Evidence Factor Factors high viral load Hospitalization Imdevimab in viral Intervention Logistic regression mAb mAbs Mild-to-moderate Model Modification monoclonal antibodies monoclonal antibody Nasopharyngeal swab negative RT-PCR not used Observational data occurred outcome Outpatient outpatients Patient PCR test Primary outcome Probability progression reduced risk reduction Relative risk risk reduction RT-PCR test SARS-CoV-2 Stratification subject target Treatment Trial two group two groups vaccination variants variants of concern Viral Viral load viral load reduction virological response VOCs was measured was used were used [DOI] 10.3389/fimmu.2022.868020 PMC 바로가기 [Article Type] Clinical Trial
Halo-A Universal Fluorescence Reader Based Threat Agent Detection Platform-A Proof of Concept Study Using SARS-CoV-2 AssaysHalo-A 범용 형광 판독기 기반 위협 에이전트 탐지 플랫폼-SARS-CoV-2 분석을 사용한 개념 증명 연구Article Published on 2022-04-122022-09-11 Journal: Frontiers in Public Health [Category] COVID19(2023년), SARS, 변종, 치료기술, 치료제, [키워드] agent amplification Antigen Asymptomatic Chain Reaction clinical samples colloidal gold comparable complex concept conditions Critical curtail delta variant demonstrated detection diagnostic diagnostics disease equipment europium extreme feasible Fluorescence gold gold standard Halo handheld reader immunoassay Infection inherent lack lateral flow lateral flow immunoassay less limit of detection Mobile App Mutation nasal PCR PCR test PCR tests performance performed platform point of care polymerase chain reaction proof public health rapid antigen test Rapid antigen tests reporter Reporting SARS CoV-2 SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 variant SARS-CoV-2 variants sensitivity Sensitivity and specificity TCID tested threat Transmission turnaround times Universal variant virus virus variant [DOI] 10.3389/fpubh.2022.852083 PMC 바로가기 [Article Type] Article
Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses인도 델타(B.1.617.2) 변이형 급증 시 SARS-CoV-2 감염에 대한 ChAdOx1 nCoV-19 백신의 효과: 테스트 음성, 사례 대조군 연구 및 백신 접종 후 면역 반응에 대한 기계론적 연구Article Published on 2022-04-012022-09-11 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), SARS, 변종, 치료법, [키워드] 95% CI addition adjusted Alpha antibody Antigen B.1.1.7 B.1.351 B.1.617.1 B.1.617.2 Beta Biotechnology case-control study CD4 CD8 T-cell response CD8 T-cell responses cellular Cellular immune response ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine Complete conserved Control Council COVID-19 COVID-19 vaccine delta variant Department disease effective Effectiveness geometric mean geometric mean titre healthy Humoral immunity immune protection immune response immune responses In-vitro India individual Industrial infected individuals laboratory-confirmed SARS-CoV-2 infection Mild Mild disease moderate-to-severe COVID-19 negative RT-PCR neutralisation neutralising antibody neutralising antibody response Neutralising antibody responses participant PCR test positive RT-PCR Primary outcome recipient remained Research RT-PCR test SARS-COV-2 infection SARS-CoV-2 variant SARS-CoV-2 variants secondary outcome Secondary outcomes single dose Spike protein Spike-specific T-cell responses T-cell immune response T-cell immune responses T-cell Response tested the spike protein vaccinated individuals vaccination Vaccine variant variant of SARS-CoV-2 variants VoC VOCs wild-type SARS-CoV-2 with mild disease [DOI] 10.1016/S1473-3099(21)00680-0 PMC 바로가기 [Article Type] Article
Post COVID-19 infection neuromyelitis optica spectrum disorder (NMOSD): A case report-based systematic reviewReview article Published on 2022-04-012022-10-05 Journal: Multiple sclerosis and related disorders [Category] COVID19(2023년), SARS, 유전자 메커니즘, [키워드] article articles Case report Central nervous system chest imaging CNS collected Coronaviridae COVID-19 COVID-19 infection database develop Devic disease disorder English etiologies evaluate Immunoglobulin inclusion criteria loss of vision Neurological disorders Neuromyelitis Optica Neuromyelitis optica spectrum disorder NMOSD Novel coronavirus Other Patient PCR test performed reported review SARS-CoV-2 selected Symptom systematic review Trigger viral infection virus weakness Web of Science were excluded [DOI] 10.1016/j.msard.2022.103697 [Article Type] Review article
Investigation of the Presence of SARS-CoV-2 in Aerosol After Dental Treatment치과 치료 후 에어로졸 내 SARS-CoV-2 존재 조사Randomized Controlled Trial Published on 2022-04-012022-09-11 Journal: International dental journal [Category] COVID19(2023년), SARS, 임상, 치료기술, [키워드] added addition aerosol Analysis assigned canine Canine tooth Chain Reaction Contamination COVID-19 COVID-19 contamination COVID-19 patients dental during treatment Elimination investigation Laboratory Operating room patients with COVID-19 PCR PCR test performed polymerase chain polymerase chain reaction positive test result Presence Prevent Randomly real-time polymerase chain reaction removal RT-PCR RT-PCR test SARS-CoV-2 Scaling Simulation specimen specimens suction tooth transport medium Treatment Viral transport medium Volume was used [DOI] 10.1016/j.identj.2021.05.002 PMC 바로가기 [Article Type] Randomized Controlled Trial
Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial합성 다항원 변형 백시니아 바이러스 앙카라 기반 COVID-19 백신(COH04S1)의 안전성 및 면역원성: 공개 및 무작위 배정, 1상 시험Clinical Trial Published on 2022-04-012022-09-11 Journal: The Lancet. Microbe [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료법, [키워드] 95% CI Administered Adults Analysis Anxiety assigned baseline body-mass body-mass index boost Cellular responses center city Cohort Comprehensive Concentration COVID-19 vaccine development dose drug eight fatigue female Fever Fisher Fisher's exact test FIVE followed by foundation Future GRADE grade 3 Haematology healthy High dose High-dose Hope IgG immunogenicity immunological increase in initiated injection interferon interferon-γ Intramuscular injection less limit low dose low-dose medium dose modified vaccinia virus modified vaccinia virus Ankara Moss negative pregnancy test nine nucleocapsid nucleocapsid antigens nucleocapsid protein nucleocapsid-specific antibody Open-label outcome participant PCR test Phase 1 phase 1 trial Placebo placebo group plaque-forming unit plaque-forming units poxvirus pregnancy test Primary outcome provided randomised Randomly receive Registered reported risk Safety SARS-CoV-2 antibody SARS-CoV-2 neutralising antibodies SARS-CoV-2 neutralising antibody SARS-CoV-2 spike Secondary objectives secondary outcome secreting Seroconversion seroconversion rate seroconversion rates Seven severe adverse event severe adverse events Spike protein statistical T cell T cells T-cell responses titre Tolerability Trial troponin USA vaccination Vaccine Viral viral neutralisation was done was measured was tested [DOI] 10.1016/S2666-5247(22)00027-1 PMC 바로가기 [Article Type] Clinical Trial
Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trialRandomized Controlled Trial Published on 2022-04-012022-10-04 Journal: Clinical microbiology and infection : the official [Category] 신약개발, 임상, [키워드] 1:1 28-day mortality 95% CI acute respiratory syndrome Admissions adverse events assigned clinical clinical recovery clinical trial coronavirus coronavirus disease COVID-19 did not reduce double-blind double-blinded enrolment evaluate Favipiravir hazard ratio Hospital admission Hospitalization intensive care interim analysis interquartile range male matching placebo median age median time Mild mild case mild COVID-19 mild COVID-19 patient monitoring board multicentre negative RT-PCR no difference Non-severe SARS-CoV-2 Non-severe SARS-CoV-2. participant Patient PCR test PCR-confirmed Placebo placebo-controlled clinical trial placebo-controlled trial Primary outcome Randomized receive recruited reduce reducing SARS-CoV-2 Saudi Arabia secondary outcome Seven severe adverse events symptom resolution the placebo group therapy Treatment treatment group Trial two group viral clearance [DOI] 10.1016/j.cmi.2021.12.026 PMC 바로가기 [Article Type] Randomized Controlled Trial
Rapid detection of the widely circulating B.1.617.2 (Delta) SARS-CoV-2 variant널리 유통되고 있는 B.1.617.2(델타) SARS-CoV-2 변이체의 신속한 탐지Article Published on 2022-04-012022-09-11 Journal: Pathology [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘, 치료기술, 치료법, 치료제, [키워드] addition Alpha Amino acid amino acids approach average B.1.1.7 B.1.617.2 CDC center Chain Reaction characteristic circulating conjunction Control coronavirus COVID-19 D950N Deletion Delta Delta COVID-19 variant disease control disease severity gene deletion Genes Genome sequencing genomic genomic sequencing gold gold standard hospitalisation hospitalisations Immune escape increase in increases in India L452R Lineage lineages Mutation Nucleocapsid gene P681R PCR test platform polymerase chain polymerase chain reaction positive positive sample pre-screen prevention randomly selected sample Rapid reported resource reverse transcription RNase P RT-PCR RT-PCR test S gene deletion S-gene SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants Spike protein strain Strains syndrome System T478K the spike protein The United States United States university USA variant Whole genome sequencing [DOI] 10.1016/j.pathol.2022.01.001 PMC 바로가기 [Article Type] Article